Highest-materiality recent filing
Iterum Therapeutics to be delisted from Nasdaq on April 1 after winding-up petition
Nasdaq will suspend ITRM shares at open on April 1, 2026; Form 25-NSE to follow.
Filed winding-up petition in Irish High Court; joint provisional liquidators appointed (Damien Murran, Jennifer McMahon of Teneo).
Iterum Therapeutics requests Nasdaq hearing to appeal delisting; warns of possible wind-down
On March 3, 2026, Iterum requested a hearing before Nasdaq Hearings Panel to appeal delisting for failure to maintain $1.00 bid price.
Iterum Therapeutics receives Nasdaq delisting notice; shares to suspend Mar 5, 2026
Received delisting determination letter on Feb 24, 2026 for failing minimum bid price of $1.00 per share.
Iterum shareholders reject all four EGM proposals; company warns of possible wind-down
Shareholders voted against increasing authorized share capital (12.8M for vs 17.9M against).
Iterum Therapeutics receives Nasdaq delisting notice for MVLS below $35M
Nasdaq notified Iterum on Dec 11, 2025 that MVLS <$35M for 30 consecutive business days; given 180 days until June 9, 2026 to regain compliance.
Iterum Therapeutics Q3 2025: ORLYNVAH launch nets $0.4M revenue; cash runway extended to Q2 2026
Net product revenue of $0.4M from ORLYNVAH launch in August 2025; 2026 sales guidance $5M-$15M.
Iterum files $20M ATM offering; ORLYNVAH launched Aug 2025 with modest sales expected
Filed prospectus supplement for ATM offering of up to $20M aggregate gross proceeds (max ~21.8M ordinary shares).
Iterum shareholders reject say-on-pay, share increase, and equity plan at AGM
David Kelly elected Class I director with 10.8M for, 2.8M against, 0.7M abstain, 8.2M broker non-votes.
Iterum Therapeutics receives Nasdaq delisting notice for bid price below $1.00
Nasdaq notice for non-compliance with minimum bid price rule; shares traded below $1.00 for 30 consecutive business days.
Iterum launches ORLYNVAH, first oral penem antibiotic in U.S., for uUTI
FDA approved ORLYNVAH in Oct 2024; commercial launch announced Aug 20, 2025.
Iterum reports Q2 net loss $6.5M; ORLYNVAH launch on track for August 2025
Net loss $6.5M (non-GAAP $5.1M) vs $5.0M prior year; cash $13.0M at June 30, 2025.
Iterum Therapeutics enters 5-year manufacturing supply agreement with ACS Dobfar for ORLYNVAH
Agreement covers commercial manufacture and supply of ORLYNVAH bilayer tablets and sulopenem etzadroxil bulk drug substance.
Iterum sets 2025 AGM for Sept 10; shareholder proposals due July 28
Annual General Meeting scheduled for September 10, 2025.
Iterum Therapeutics enters commercialization agreement with EVERSANA for ORLYNVAH in US
Eversana will be exclusive provider of sales, marketing, logistics, regulatory, and medical affairs services for ORLYNVAH.
Iterum extends $20M Pfizer milestone payment to Oct 2029; interest rises to 10%
$20M regulatory milestone due Oct 2026 extended to Oct 2029 via amended promissory note.
Iterum Therapeutics Q1 net loss $4.9M; preparing for ORLYNVAH launch by Q4 2025
Net loss of $4.9M in Q1 2025 vs $7.1M in Q1 2024; non-GAAP net loss $3.3M vs $5.8M.
Gross proceeds of $5.0M from sale of 5,555,556 shares/warrants at $0.90 each.
Iterum Therapeutics appoints Joseph Whalen to board; David Kelly named Chairman
Joseph J. Whalen appointed as Class III director effective March 10, 2025; term expires at 2027 AGM.
approved the appointment of Joseph J. Whalen as a member of the Board, effective as of March 10, 2025.
the Board also appointed David Kelly, an existing director of the Board, as Chairman of the Board, effective as of March 10, 2025.
Max materiality 1.00 · Median 0.65 · Most common event other_material